kasugamycin has been researched along with rifampin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adachi, Y; Kawamura, F; Kim, JY; Masuda, K; Nanamiya, H; Ochi, K; Okamoto, S; Tanaka, Y; Tokuyama, S; Wang, G | 1 |
| Deaves, JK; Maguire, BA; Wild, DG | 1 |
| Chaudhuri, S; Chen, Y; Chen, YX; Dartois, VA; Gardner, M; Javid, B; Kawaji, Q; Li, L; Li, YY; Martinot, AJ; Pan, M; Rubin, EJ; Su, HW; Toosky, MN; Zhu, JH; Zimmerman, M | 1 |
3 other study(ies) available for kasugamycin and rifampin
| Article | Year |
|---|---|
Inactivation of KsgA, a 16S rRNA methyltransferase, causes vigorous emergence of mutants with high-level kasugamycin resistance.
Topics: Aminoglycosides; Bacillus subtilis; Bacterial Proteins; Drug Resistance, Microbial; Methyltransferases; Mutation; RNA, Ribosomal, 16S | 2009 |
Some properties of two erythromycin-dependent strains of Escherichia coli.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Chloramphenicol; Culture Media; DNA, Bacterial; Erythromycin; Escherichia coli; Phenotype; Rifampin; RNA, Bacterial; Spectinomycin; Tetracycline | 1989 |
Kasugamycin potentiates rifampicin and limits emergence of resistance in
Topics: Aminoacylation; Aminoglycosides; Animals; Drug Resistance, Bacterial; Drug Synergism; Edeine; Injections, Intraperitoneal; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Organ Specificity; Protein Biosynthesis; Rifampin; RNA, Transfer; Streptomycin; Tuberculosis | 2018 |